CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
Public ClinicalTrials.gov record NCT01673672. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the therapeutic potential and safety/tolerability of study drug (CYT003) at 3 dose levels versus placebo in patients with persistent moderate to severe allergic asthma not sufficiently controlled on current standard controller therapy. Altogether 360 patients randomized to 4 treatment groups will be included. The study compares three dose strength with placebo. Each patient receives 7 injections of study drug or undistinguishable placebo. Key outcome measures are patient reported parameters on their asthma.
Study identification
- NCT ID
- NCT01673672
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 365 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2012 (Type not available)
- Primary completion
- May 2014 (Actual)
- Completion
- May 2014 (Actual)
- Last update posted
- May 14, 2014
2012 – 2014
United States locations
- U.S. sites
- 21
- U.S. states
- 20
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cytos Investigator Sites | Los Angeles, Huntington Beach, San Jose | California | — | — |
| Cytos Investigator Sites | Walnut Creek, San Diego, Riverside, Fountain Valley | California | — | — |
| Cytos Investigator Sites | Colorado Springs, Denver | Colorado | — | — |
| Cytos Investigator Sites | Waterbury | Connecticut | — | — |
| Cytos Investigator Sites | Miami, Tallahassee | Florida | — | — |
| Cytos Investigator Sites | Albany | Georgia | — | — |
| Cytos Investigator Sites | South Bend | Indiana | — | — |
| Cytos Investigator Sites | Metairie | Louisiana | — | — |
| Cytos Investigator Sites | Bangor | Maine | — | — |
| Cytos Investigator Sites | Bethesda | Maryland | — | — |
| Cytos Investigator Sites | North Dartmouth | Massachusetts | — | — |
| Cytos Investigator Sites | St Louis | Missouri | — | — |
| Cytos Investigator Sites | Ohmaha, Bellevue | Nebraska | — | — |
| Cytos Investigator Sites | Rochester | New York | — | — |
| Cytos Investigator Sites | Cincinnati | Ohio | — | — |
| Cytos Investigator Sites | Oklahoma City | Oklahoma | — | — |
| Cytos Investigator Sites | Eugene, Medford | Oregon | — | — |
| Cytos Investigator Sites | Providence, Warwick | Rhode Island | — | — |
| Cytos Investigator Sites | Spartanburg, Summerville | South Carolina | — | — |
| Cytos Investigator Sites | San Antonio | Texas | — | — |
| Cytos Investigator Sites | Richmond | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01673672, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 14, 2014 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01673672 live on ClinicalTrials.gov.